Citizens Financial Services has reaffirmed its positive stance on Altimmune (ALTM) after the biotech disclosed additional data on its pemvidutide program. The company’s latest pre‑clinical results suggest a broader therapeutic window and improved pharmacokinetics, reinforcing the view that pemvidutide could become a key player in the treatment of chronic inflammatory diseases.
Citizens analysts highlighted that the new data supports the company’s long‑term growth thesis and maintains the current “Buy” recommendation with a target price that remains unchanged.
In broader market terms, investors are keeping a close eye on commodity prices as they can influence inflation expectations. Gold traded at $3,896.39, up 18.73 points or 0.48%. Silver closed at $49.970, down 0.095 points or 0.19%. WTI crude fell 0.14 points to $88.60, while Brent crude edged up 0.15 points to $95.97. Copper slipped 0.0640 to $6.1320, and aluminum dropped 26.90 points to $2,992.00. Natural gas was down 0.061 to $3.279.
With the market’s focus on both macroeconomic indicators and corporate earnings, Altimmune’s continued progress on pemvidutide remains a key catalyst for its stock performance.


